Useful Stock Trading Clip:Stock Trading Analysis HGSI Human Genome Sciences Comments on Benlysta FDA Approval
| www.StockMarketFunding.com Stock Trading Analysis (HGSI) Human Genome Sciences Comments on Benlysta FDA Approval. Human Genome Sciences CEO Cautions On Lupus Drug Launch By Thomas Gryta Of DOW JONES NEWSWIRES SAN FRANCISCO (Dow Jones)--Human Genome Sciences Inc. (HGSI) is expecting regulatory approval of its lupus drug in March, but Chief Executive Thomas Watkins is trying to make sure investors don't get too excited about the drug's launch. Benlysta, a drug being develop by Human Genome and GlaxoSmithKline PLC (GSK), would be the first drug for the autoimmune disease in more than 50 years. After an earlier delay, the Food and Drug Administration is set to make a decision in March, and Wall Street generally expects sales to exceed $1 billion a year. Watkins isn't worried about the drug selling--earlier this week, the company projected "multibillion-dollar annual revenues" by 2015--but he has become concerned about investor perceptions of the launch's speed in recent months. "We've been trying to manage down expectations a bit," he said in an interview Wednesday at the JP Morgan healthcare conference in San Francisco. "Often with drug launches, the expectations are so high that for the first couple of quarters it is almost impossible to meet the expectations," he said. Companies such as Amgen Inc. (AMGN) and Dendreon Corp. (DNDN) faced Wall Street scrutiny in 2010 from slower-than-expected launches of new products that are expected to be blockbusters eventually. The ...Share Trading Facts: Using the Internet, specialized software, and a personal computer, share traders/investors make use of technical analysis and fundamental analysis to help them in making decisions. Depending on the nature of each national or state legislation involved, a large array of fiscal obligations must be respected, and taxes are charged by jurisdictions over those transactions, dividends and capital gains that fall within their scope. In a normal distribution of investors, many academics believe that the richest are simply outliers in such a distribution. |
Duration: 00:11:06 Rating:   View: 82From: StockMarketFunding Keywords: stock trading, trading analysis, HGSI, human genome, benlysta, FDA, approval, benstlya sales, sales benlysta, benlysta approval, drug, drug launch, benlysta launch |
Related Video
Star:
Star:
Star:
Star:
Star:
Star:
Star:
Star:
Star:
Star:
Star:
Star:
Star:
Star:
Star:
Star:
Star:
Star:
Star:
Star: